Abstract 71P
Background
Ovarian cancer is the most common cause of death from gynecological malignancies. In the early stages, women are generally asymptomatic or have non-specific symptoms, making early-stage ovarian cancer undiagnosed. The different investigations reported the effect of polymorphisms in folate metabolism genes on ovarian cancer risk in different ethnicities. The aim of the current study was to analyze associations between the polymorphisms of key folate metabolism enzyme genes, methylene tetrahydrofolate reductase (MTHFR) and 5,10-methylenetetrahydrofolate dehydrogenase (MTHFD1) (C677T and G1958A, respectively) and ovarian cancer risk in Georgia. In addition, we assessed DNA methylation levels in ovarian cancer patients with polymorphic variants of these genes.
Methods
30 cancer patients and 30 healthy controls were included in this study. All patients and controls provided informed consent before being enrolled in the study. This study was approved by the Ethics Committee of the Tbilisi State Medical University. Genomic DNA was isolated from peripheral blood using a commercial kit (Qiagen, USA). Single Nucleotide Polymorphism (SNP) genotyping was performed using TaqMan Assay (Thermo Scientific, USA). Global DNA methylation was analyzed using the Global DNA Methylation Assay Kit (Abcam, MA, USA).
Results
The results suggest that there was a high association between MTHFD1 gene G1958A variant and the risk of ovarian cancer in Georgian patients (p<0.001). No statistically significant differences in allele and genotype frequencies of MTHFR gene C677T SNP were observed between patients and controls (p > 0.05). In addition, global DNA methylation in individuals with CT+TT genotypes were found to be reduced compared to CC genotypes in respect to the C677T variant of MTHFR gene.
Conclusions
In our study, we did not find any association between the MTHFR gene C677T polymorphism and ovarian cancer, however the AA genotype of MTHFD1 gene G1958A variant associated with increased risk of ovarian cancer. We, also, found that CT and TT genotypes of MTHFR gene C677T variant are associated with altered DNA methylation in ovarian cancer patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
This study was supported by the Shota Rustaveli National Science Foundation of Georgia (grant number #FR-21-17599).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
146P - The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis
Presenter: Eric Nakamura
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Identification of potential predictive biomarkers for ovarian cancer chemotherapy response
Presenter: Alsina Nurgalieva
Session: Cocktail & Poster Display session
Resources:
Abstract
149P - Rare RAS mutations are associated with recurrence patterns and recurrence-free survival in colon cancer: First results from Morocco
Presenter: Fatima Agy
Session: Cocktail & Poster Display session
Resources:
Abstract
151P - Development of a predictive model for response to neoadjuvant chemoradiation therapy of rectal cancer using the immunologic profile
Presenter: Eun Shin
Session: Cocktail & Poster Display session
Resources:
Abstract
152P - Biomarkers of neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
Presenter: Cibele Masotti
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - BRAF variants and therapy outcomes in melanoma
Presenter: Eftychia Chatziioannou
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - The impact of proton pump inhibitors in the prognosis of patients with non-metastatic nasopharyngeal carcinoma
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
155P - Use of machine learning for the identification of molecular biomarkers to predict response to neoadjuvant chemotherapy in locally advanced breast cancer patients
Presenter: María Del Río Pisula
Session: Cocktail & Poster Display session
Resources:
Abstract
156P - Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic
Presenter: Michal Eid
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - PCM4EU academy: An educational program for precision oncology
Presenter: Loic Verlingue
Session: Cocktail & Poster Display session
Resources:
Abstract